Download PDF
Arthritis und Rheuma 2017; 37(02): 120-123
DOI: 10.1055/s-0037-1618418
Neues zur rheumatologischen Pharmakotherapie – biologische DMARDs
Schattauer GmbH

Aktueller Stand der Therapie der rheumatoiden Arthritis mit biologischen DMARDs

Eine RezensionBiological DMARD in the treatment of rheumatoid arthritisA review
K. Krüger
1   Rheumatologisches Praxiszentrum St. Bonifatius, München
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
  PDF Download  Permissions and Reprints

Zusammenfassung

Biologika werden in der Rheumatologie seit 17 Jahren eingesetzt. Sie haben die Behandlungsmöglichkeiten bei Krankheiten wie der rheumatoiden Arthritis (RA) dramatisch verbessert und entscheidend dazu beigetragen, dass heute die Remission bei dieser Erkrankung das Behandlungsziel darstellt. Gegenwärtig sind aus dieser Wirkstoffgruppe neun Substanzen für die Behandlung der RA zugelassen, fünf davon hemmen TNF-α, je eines Interleukin-1, Interleukin-6, B-Lymphozyten und die Aktivierung von T-Lymphozyten. Zusätzlich stehen aktuell drei Infliximab-Bio -similars und ein Etanercept-Biosimilar zur Verfügung. Biologika kommen bei der RA bei Patienten mit ungünstiger Prognose als Zweitlinientherapie (in der Regel im Fall einer nicht ausreichend wirksamen Starttherapie mit Methotrexat = MTX) zum Einsatz, in den übrigen Fällen sollten sie bei Versagen konventioneller DMARDs spätestens als Drittlinientherapie eingesetzt werden. Sie sollten kombiniert mit MTX verwendet werden, so-fern dieser Kombinationspartner zur Verfügung steht. Bei MTX-Kontraindikation oder -Unverträglichkeit sind einige der Substanzen auch für die Monotherapie zugelassen, die beste Wirksamkeit bieten hier Tocilizumab und in zweiter Linie Etanercept. Bei Unwirksamkeit des ersten Biologikums ist ein Switch auf eine andere Substanz aus der Gruppe oft erfolgreich.

Summary

Biologic Disease-modifying antirheumatic drugs (bDMARD) are used since 2000 and have improved treatment possibilities in rheumatoid arthritis (RA) dramatically ensuring remission being a realistic treatment target today. BDMARD group so far includes five TNF-α inhibitors as well as inhibitors of Interleukin 1, Interleukin 6, B Lymphocytes and T-cell-activation, in addition three Infliximab biosimilars and one etanercept biosimilar. In RA bDMARDs should be used as second-line treatment if starting treatment (normally methotrexate [MTX]) fails in patients with unfavourable prognosis and as third-line treatment in all other cases. If possible, bDMARDs should be combined with MTX, in cases of MTX contraindications or adverse effects monotherapy with tocilizumab or etanercept is the best option. If the first bDMARD has failed, switch to a second one is possible and successful in many cases.

Schlüsselwörter

Rheumatoide Arthritis - Therapie - biologische DMARDs

Keywords

Rheumatoid arthritis - treatment - biological DMARD
 

  • Literatur

  • 1 Fiehn C, Krüger K. Management der rheumatoiden Arthritis. Internist 2016; 57: 1042-1051.
    CrossrefPubMedGoogle Scholar
  • 2 Schneider M, Krüger K. Rheumatoid arthritis - early diagnosis and disease management. Dtsch Ärztebl Int 2013; 110: 477-484.
    PubMedGoogle Scholar
  • 3 Singh JA, Hossain A, Tanjong Ghogomu E. et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2016; 13 (05) CD012183
    Google Scholar
  • 4 Schiff M, Weinblatt ME, Valente R. et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014; 73: 86-94.
    CrossrefPubMedGoogle Scholar
  • 5 Porter D, van Melckebeke J, Dale J. et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 2016. online May 16
    Google Scholar
  • 6 Smolen JS, Aletaha D, McInnes IB. Rheumatoid Arthritis. Lancet 2016; 388: 2023-2038.
    CrossrefPubMedGoogle Scholar
  • 7 Krüger K. Kombinationsbehandlung von Methotrexat mit DMARDs oder Biologika - Aktueller Stand. Z Rheumatol 2011; 70: 114-122.
    CrossrefPubMedGoogle Scholar
  • 8 Manders SHM, Kievit W, Jansen TLTA. et al. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry. J Rheumatol 2016; 43: 1787-1794.
    CrossrefPubMedGoogle Scholar
  • 9 Behrens F, Rossmanith T, Koehm M. et al. Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study) Arthritis Rheum. 2016; 68 (Suppl. 10) Abst 954
    PubMedGoogle Scholar
  • 10 Deutsches Rheumaforschungs-Zentrum Berlin: Daten der Kerndokumentation 2014. Daten noch unpubliziert
  • 11 Gabay C, Emery P, van Vollenhoven R. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381: 1541-1550.
    CrossrefPubMedGoogle Scholar
  • 12 Burmester GR, Rigby WF, van Vollenhoven RF. et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 2016; 75: 1081-1091.
    PubMedGoogle Scholar
  • 13 Bijlsma JWJ, Welsing PMJ, Woodworth TG. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 2016; 388: 343-355.
    CrossrefPubMedGoogle Scholar
  • 14 Tarp S, Furst DE, Dossin A. et al. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum 2016; doi.org/10.1016/j.semarthrit.2016.09.003. Reference YSARH51106
    Google Scholar
  • 15 Dörner T, Strand V, Cornes P. et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016; 75: 974-982.
    CrossrefPubMedGoogle Scholar
  • 16 Goll GL, Olsen IC, Jorgensen KK. et al. Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway. Arthritis Rheumatol 2016; 68 (Suppl. 10) Abstr 19L
    Google Scholar
  • 17 Krüger K, Wollenhaupt J, Albrecht K. et al. S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012. Z Rheumatol 2012; 71: 592-603.
    CrossrefPubMedGoogle Scholar
  • 18 Smolen JS, Landewe R, Breedveld FC. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
    PubMedGoogle Scholar
  • 19 Koga T, Okada A, Fukuda T. et al. Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice. Medicine 2016; 95: e3476
    CrossrefPubMedGoogle Scholar
  • 20 Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 2013; 8: 87-100.
    PubMedGoogle Scholar
  • 21 Gottenberg JE, Courvoisier DS, Hernandez MV. et al. Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. Arthritis Rheum 2016; 68: 1346-1352.
    Google Scholar
  • 22 Harrold LR, Reed GW, Kremer JM. et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 2015; 74: 430-436.
    CrossrefPubMedGoogle Scholar
  • 23 Harrold LR, Reed GW, Magner R. et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther 2015; 17: 256
    CrossrefPubMedGoogle Scholar
  • 24 Gottenberg JE, Brocq O, Perdriger A. et al. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug. A Randomized Clinical Trial. JAMA 2016; 316: 1172-1180.
    CrossrefPubMedGoogle Scholar
  • 25 Chatzidionysiou K, Askling J, Eriksson J. et al. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 2015; 74: 890-896.
    PubMedGoogle Scholar
  • 26 Krüger K, Edelmann E. Therapieabbau bei stabil eingestellter rheumatoider Arthritis - Stand des Wissens. Z Rheumatol 2015; 74: 414-420.
    CrossrefPubMedGoogle Scholar
  • 27 Schett G, Emery P, Tanaka Y. et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016; 75: 1428-1437.
    CrossrefPubMedGoogle Scholar
  • 28 Haschka J, Englbrecht M, Hueber AJ. et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016; 75: 45-51.
    CrossrefPubMedGoogle Scholar
  • 29 van Vollenhoven RF, østergaard M, Leirisalo-Repo M. et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016; 75: 52-58.
    PubMedGoogle Scholar
  • 30 Emery P, Hammoudeh M, FitzGerald O. et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014; 371: 1781-1792.
    CrossrefPubMedGoogle Scholar
  • 31 Brahe CH, Krabbe S, østergaard M. et al. Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission - 1-Year Results of a Guideline-Directed Longitudinal Cohort Study. Arthritis Rheumatol 2016; 68 (Suppl. 10) Abstr 3013
    Google Scholar
  • 32 Fleischmann R, van Adelsberg J, Lin Y. et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol 2017; 69: 277-290.
    CrossrefPubMedGoogle Scholar
  • 33 Strand V, Kosinski M, Chen CI. et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther 2016; 18: 198
    CrossrefPubMedGoogle Scholar
  • 34 Burmester GR, Lin Y, Patel R. et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 2016; online Nov 17
    PubMedGoogle Scholar
  • 35 Lazzerini PE, Capecchi PL, Guidelli GM. et al. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Develop Therapy 2016; 10: 3083-3098.
    Google Scholar